PVCT - Provectus reports synthesis of new halogenated xanthene small molecule

Provectus (OTC:PVCT) said it has developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The company said its intellectual property comprises an entire class of related HX molecules that are proprietarily-synthesized. "We are excited to have produced a new halogenated xanthene, further expanding our medical science platform. We look forward to developing this small molecule into a viable Provectus drug product candidate," said Dominic Rodrigues, vice chair of board.

For further details see:

Provectus reports synthesis of new halogenated xanthene small molecule